Enfusion (NYSE:ENFN) Hits New 1-Year High - What's Next?

Enfusion, Inc. (NYSE:ENFN - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $11.80 and last traded at $11.38, with a volume of 160693 shares trading hands. The stock had previously closed at $11.07.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ENFN shares. Stifel Nicolaus upped their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. William Blair reaffirmed a "market perform" rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Piper Sandler upped their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a research note on Monday, December 23rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, Enfusion currently has an average rating of "Hold" and an average price target of $10.50.

Enfusion Stock Performance

The firm's 50 day moving average price is $10.82 and its two-hundred day moving average price is $9.64. The firm has a market cap of $1.48 billion, a PE ratio of 287.45, a PEG ratio of 1.85 and a beta of 0.96.

Insider Activity

In other news, CFO Bradley Herring sold 4,134 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $41,877.42. Following the transaction, the chief financial officer now directly owns 266,369 shares in the company, valued at approximately $2,698,317.97. This represents a 1.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Oleg Movchan sold 2,771 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the transaction, the chief executive officer now owns 526,702 shares in the company, valued at approximately $5,335,491.26. This represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,367 shares of company stock valued at $591,335 in the last 90 days. Company insiders own 36.44% of the company's stock.

Hedge Funds Weigh In On Enfusion

Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its holdings in shares of Enfusion by 7.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company's stock worth $9,770,000 after acquiring an additional 70,367 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Enfusion by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock worth $9,265,000 after buying an additional 61,032 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Enfusion by 612.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company's stock worth $1,974,000 after buying an additional 178,821 shares in the last quarter. Barclays PLC lifted its holdings in Enfusion by 251.4% during the 3rd quarter. Barclays PLC now owns 86,039 shares of the company's stock worth $817,000 after buying an additional 61,554 shares in the last quarter. Finally, PDT Partners LLC acquired a new stake in Enfusion during the 3rd quarter worth approximately $867,000. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.